Skip to content
Research/Metabolic Glp1/Liraglutide

Liraglutide

compound

preliminary evidencePublic

First-generation long-acting GLP-1 analog. FDA-approved for T2D (Victoza) and obesity (Saxenda 3mg). Daily injection. Brand names: Victoza, Saxenda.

Category: Metabolic Glp1·Updated 5/20/2026
OverviewScienceClinicalSafetyPapersProtocolsOutcomes

Liraglutide

First-generation long-acting GLP-1 analog. FDA-approved for T2D (Victoza) and obesity (Saxenda 3mg). Daily injection. Brand names: Victoza, Saxenda.

ScienceComing soon
ClinicalComing soon
SafetyComing soon
PapersComing soon
ProtocolsComing soon
OutcomesComing soon